4722-08-1

Usage

Type

Psychedelic phenylethylamine chemical compound

Structural relation

Related to mescaline

Synthesized by

Alexander Shulgin

Hallucinogenic effects

Known for inducing visual and auditory hallucinations, altered thoughts and perceptions, and euphoria when ingested

Use

Commonly used recreationally as a hallucinogenic drug

Classification

Classified as a controlled substance in many countries due to its psychoactive properties

Scientific research

Used to study the effects of psychedelics on the brain and consciousness

Potential risks

Potential for abuse and adverse health effects

Regulation

Use is heavily regulated and restricted

Upstream product

• 57542-90-2 (dimethoxy-3,4 phenyl)-2 methoxy-2 nitro-1 ethane 
• 874518-74-8 4-(2-bromo-1-methoxy-ethyl)-1,2-dimethoxy-benzene 
• 64-19-7 acetic acid 
• 4230-93-7 1,2-dimethoxy-4-(2-nitro-vinyl)-benzene 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 4230-93-7 3,4-dimethoxynitrostyrene 

Downstream Products

• 460743-81-1 N-[2-(3,4-dimethoxyphenyl)-2-methoxyethyl]benzamide 
• 57542-96-8 N-p-Chlorphenacyl-β-methoxyhomoveratrylamin 
• 57542-93-5 N-o-Chlorphenacyl-β-methoxyhomoveratrylamin 
• 109935-91-3 1-(2,3-dimethoxybenzyl)-6,7-dimethoxyisoquinoline 
• 23818-73-7 6,7-dimethoxy-1-benzylisoquinoline 
• 859078-25-4 1-(3-benzyloxy-4-methoxy-benzyl)-6,7-dimethoxy-isoquinoline 
• 18694-10-5 1-(3'-hydroxy-4'-methoxybenzyl)-6,7-dimethoxyisoquinoline 
• 88741-64-4 2-(6,7-Dimethoxy-isoquinolin-1-yl)-4-methoxy-benzoic acid methyl ester 
• 88741-63-3 1-(2'-carboxy-5'-methoxyphenyl)-6,7-dimethoxyisoquinoline 
• 83287-02-9 menisporphine 
• 88741-68-8 5,6,10-trimethoxy-7H-dibenzoquinolin-7-one 
• 88741-62-2 1-(2'-cyano-5'-methoxyphenyl)-6,7-dimethoxyisoquinoline 
• 83287-05-2 2-(6,7-dimethoxy-isoquinolin-1-yl)-5-methoxybenzonitrile 
• 88741-65-5 methyl 2-(6,7-dimethoxyisoquinolin-1-yl)-5-methoxybenzoate 

Relevant academic research and scientific papers

1-(4-Aminobenzyl)- and 1-(4-aminophenyl)isoquinoline derivatives: Synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors

In an effort to increase the specificity of the potent phosphodiesterase inhibitor papaverine, we synthesized two series of novel 1-(4-aminobenzyl)- and 1-(4-aminophenyl)isoquinoline derivatives, incorporating alkylating moieties on the amine substituents. These compounds were evaluated for their inhibitory action on phosphodiesterase preparations from bovine heart and rat cerebral cortex. Studies were also conducted to determine whether these compounds were reacting with the enzymes in an irreversible manner. The compounds were potent inhibitors of the phosphodiesterases; however, no evidence was found for an irreversible inhibition.

Diazaestrones and analogs. II. Structural modifications of succinimidoethyldihydroisoquinoline, heterosteroid precursor, to establish structure-analgesic activity relationship

β-1-(succinimidoethyl)-6,7-dimethoxydihydroisoquinoline having exihibited a stronger analgesic activity than the methylester of 2-methoxy-8,13-diazaestrone, its structure has been systematically modified in view of establishing a relation between structur

New structural analogs of papaverine: 3 benzyl 6,7 dimethoxy (di and tetrahydro) isoquinolines

Syntheses of 3 benzyl 3,4 dihydroisoquinolines by cyclisation of a N acyl α benzylhomoveratrylamine by means of polyphosphoric acid ester, in boiling toluene, gave yields between 60 and 90%. While the hydrogenation of these dihydroisoquinolines to tetrahydroisoquinolines with an alkaline borohydride gave satisfactory result, their dehydrogenation into isoquinolines could not be accomplished. Pharmacological properties of the hydrobromides or hydrochlorides of the bases of the two series of the aforementioned 3 benzylisoquinolines and comparison of their activities with those of papaverine and the analogues 1 and 4 benzylisoquinolines are reported.